TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW

被引：1
作者：
Valle, P. M. [1 ]
Mosegui, G. B. [1 ]
Vianna, C. M. [2 ]
Araujo, R. L. [3 ]
Felicissimo, T. [3 ]
Lima, I. J. [4 ]
机构：
[1] Univ Fed Fluminense, Niteroi, RJ, Brazil
[2] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
[3] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil
[4] Univ Fed Itajuba, Itajuba, Brazil
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.234
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN6
引用
收藏
页码：A816 / A816
页数：1
相关论文
共 50 条
  • [1] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
  • [2] The role of Trastuzumab Emtansine as a novel-targeted therapy for HER2 breast cancer: A systematic review
    Bajaj, Nikki
    Shaaban, Hamid
    Guron, Gunwant
    Maroules, Michael
    CLINICAL CANCER INVESTIGATION JOURNAL, 2013, 2 (04): : 275 - 280
  • [3] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12) : E528 - E528
  • [4] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan
    Xumei Liu
    Yi Cai
    Wenyuan Li
    Systematic Reviews, 11
  • [5] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Cai, Yi
    Li, Wenyuan
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [6] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [7] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) : 1783 - 1791
  • [8] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06) : 696 - 697
  • [9] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [10] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
12345